Aspalathin has been already reported to suppress hyperuricemia by inhibiting xanthine oxidase activity in vitro and inosine-5′-monophosphate (IMP)-induced hyperuricemia in vivo [91]. The gene discussed is XDH; the disease is hyperuricemia.